Suppr超能文献

[多巴胺转运体:特征及病理生理学意义]

[The dopamine transporter: characterization and physiopathologic implications].

作者信息

Thibaut F, Vaugeois J M, Petit M

机构信息

Groupe de recherche sur la schizophrénie, Service Hospitalo-Universitaire, Scotteville-les-Rouen.

出版信息

Encephale. 1995 Nov-Dec;21(6):445-51.

PMID:8674469
Abstract

The dopamine transporter (DAT) is the carrier protein that transports dopamine across the presynaptic membrane. The DAT terminates the action of dopamine (DA) in the synapse via reuptake and thus regulates DA neurotransmission. The transporter has been studied by direct binding techniques using a variety of ligands which are inhibitors of DA transport. DAT binding, both in vivo (positron emission tomography) and in vitro (post mortem) may serve as a presynaptic marker to measure altered DA innervation in several neuropsychiatric diseases such as idiopathic Parkinson's disease, Tourette's disease, schizophrenia or cocaine addiction. In Parkinson's disease, a reduction in the density of binding sites could be due either to a degeneration of the terminal dopaminergic projections or to a compensatory readjustment in the level of dopamine synaptic transmission. This dopaminergic cell specific marker could also aid in attempts to elucidate the rate at which dopaminergic cells are lost in this disease. MPTP (a neurotoxin which induces a parkinsonian-like syndrome after conversion in MPP+) uses DAT to enter the neuron and exert its toxic effect which may be prevented by pretreatment with DA uptake blockers. In cocaine abuse, DAT mediates the addictive properties of cocaine. Cocaine binding sites on the carrier may be distinct from DA binding sites allowing the development of medication sparing the DA function but impairing the cocaine effects. In schizophrenia, functional DA uptake was reported to be increased in the striatum in post mortem brains, whereas the kinetic parameters of the uptake sites were unchanged using different transporter labeling ligands. Thus, this marker does not provide any evidence for the dopaminergic hypothesis, but an impairment of the DAT itself could possibly be involved in the etiology of schizophrenia. However, the possible interaction of drugs such as L-Dopa or neuroleptic treatment with transporter binding may be taken into account in the results analysis. Finally, the DAT gene is also an important candidate gene for psychiatric diseases such as schizophrenia or cocaine abuse.

摘要

多巴胺转运体(DAT)是一种载体蛋白,可将多巴胺转运过突触前膜。DAT通过再摄取终止突触中多巴胺(DA)的作用,从而调节DA神经传递。已经使用多种作为DA转运抑制剂的配体,通过直接结合技术对该转运体进行了研究。DAT结合,无论是在体内(正电子发射断层扫描)还是在体外(尸检),都可作为一种突触前标记物,用于测量几种神经精神疾病(如特发性帕金森病、图雷特氏病、精神分裂症或可卡因成瘾)中DA神经支配的改变。在帕金森病中,结合位点密度的降低可能是由于终末多巴胺能投射的退化,或者是多巴胺突触传递水平的代偿性重新调整。这种多巴胺能细胞特异性标记物也有助于阐明该疾病中多巴胺能细胞的丧失速率。MPTP(一种在转化为MPP+后可诱发帕金森样综合征的神经毒素)利用DAT进入神经元并发挥其毒性作用,而DA摄取阻滞剂预处理可预防这种毒性作用。在可卡因滥用中,DAT介导可卡因的成瘾特性。载体上的可卡因结合位点可能与DA结合位点不同,这使得能够开发出保留DA功能但损害可卡因作用的药物。在精神分裂症中,据报道,死后大脑纹状体中的功能性DA摄取增加,而使用不同的转运体标记配体时,摄取位点的动力学参数未发生变化。因此,该标记物没有为多巴胺能假说提供任何证据,但DAT本身的损害可能参与了精神分裂症的病因。然而,在结果分析中可能需要考虑L-多巴或抗精神病药物治疗等药物与转运体结合的可能相互作用。最后,DAT基因也是精神分裂症或可卡因滥用等精神疾病的重要候选基因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验